patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_797504 | REC_0010501 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 14.5 | 65 | male | 0 | 5 | 5 | 5 | alectinib 600 mg BID | 16.6 | true | MSS | 2026-03-15T05:35:59.477438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750623 | REC_0010502 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 8.3 | 77 | female | 2 | 2 | 4.1 | 5 | pembrolizumab 200 mg q3w | 17.1 | true | MSS | 2026-03-15T05:35:59.477669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931016 | REC_0010503 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.2 | 67 | female | 1 | 16 | 4.8 | 4 | osimertinib 80 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:59.477921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187848 | REC_0010504 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 16.6 | 52 | male | 0 | 9 | 5.5 | 5 | osimertinib 80 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:59.478155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_642777 | REC_0010505 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 7.9 | 66 | female | 0 | 31 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.1 | true | MSS | 2026-03-15T05:35:59.478472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893026 | REC_0010506 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 14.1 | 52 | female | 0 | 13 | 6.5 | 2 | alectinib 600 mg BID | 13.8 | false | MSI-H | 2026-03-15T05:35:59.478719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772049 | REC_0010507 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14.2 | 77 | female | 1 | 10 | 6.1 | 2 | sotorasib 960 mg daily | 22.6 | false | MSS | 2026-03-15T05:35:59.478969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262673 | REC_0010508 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.3 | 64 | male | 0 | 3 | 4 | 5 | osimertinib 80 mg daily | 6.6 | true | MSS | 2026-03-15T05:35:59.479205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394678 | REC_0010509 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 11.7 | 67 | female | 0 | 25 | 4.2 | 8 | pembrolizumab 200 mg q3w | 13.3 | true | MSS | 2026-03-15T05:35:59.479438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648084 | REC_0010510 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 16 | 4.2 | 65 | female | 0 | 8 | 7.2 | 4 | pembrolizumab 200 mg q3w | 14 | true | MSS | 2026-03-15T05:35:59.479673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332577 | REC_0010511 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 4.4 | 59 | female | 1 | 13 | 6.2 | 3 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:59.480004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698464 | REC_0010512 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 3.9 | 74 | female | 1 | 50 | 2.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 16.6 | false | MSS | 2026-03-15T05:35:59.480282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252411 | REC_0010513 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 16.1 | 55 | male | 1 | 20 | 3.7 | 5 | osimertinib 80 mg daily | 19.5 | false | MSS | 2026-03-15T05:35:59.480548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882822 | REC_0010514 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 8.3 | 69 | female | 1 | 57 | 4.9 | 7 | pembrolizumab 200 mg q3w | 11.8 | true | MSS | 2026-03-15T05:35:59.480802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622156 | REC_0010515 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15.1 | 71 | female | 1 | 8 | 5 | 6 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:59.481056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986056 | REC_0010516 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 17.2 | 78 | female | 2 | 13 | 6.8 | 2 | sotorasib 960 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:59.481304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454309 | REC_0010517 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 15 | 9 | 74 | female | 1 | 3 | 5 | 2 | sotorasib 960 mg daily | 21.2 | true | MSS | 2026-03-15T05:35:59.481536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202289 | REC_0010518 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 9.1 | 64 | male | 1 | 17 | 4.3 | 2 | sotorasib 960 mg daily | 23.8 | true | MSS | 2026-03-15T05:35:59.481876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927653 | REC_0010519 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 17.5 | 70 | male | 1 | 16 | 4.7 | 4 | pembrolizumab 200 mg q3w | 5.1 | false | MSS | 2026-03-15T05:35:59.482136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690423 | REC_0010520 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 16.1 | 56 | male | 0 | 11 | 4.4 | 5 | osimertinib 80 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:59.482374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930489 | REC_0010521 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 16 | 56 | male | 0 | 16 | 2.9 | 2 | entrectinib 600 mg daily | 18.4 | false | MSI-H | 2026-03-15T05:35:59.482628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626526 | REC_0010522 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 11.7 | 56 | female | 0 | 18 | 4.6 | 2 | entrectinib 600 mg daily | 15.7 | true | MSS | 2026-03-15T05:35:59.482862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290265 | REC_0010523 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 33 | 2.6 | 77 | female | 2 | 2 | 4.5 | 3 | pembrolizumab 200 mg q3w | 11.9 | false | MSS | 2026-03-15T05:35:59.483092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643498 | REC_0010524 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9 | 52 | female | 0 | 8 | 6.3 | 7 | sotorasib 960 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:59.483324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871606 | REC_0010525 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 9.8 | 79 | female | 2 | 11 | 4.4 | 4 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:59.483563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416391 | REC_0010526 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 5.6 | 67 | female | 0 | 13 | 4 | 1 | pembrolizumab 200 mg q3w | 18.5 | true | MSS | 2026-03-15T05:35:59.483809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442974 | REC_0010527 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 16.6 | 73 | female | 2 | 16 | 4.7 | 2 | osimertinib 80 mg daily | 16.9 | true | MSI-H | 2026-03-15T05:35:59.484052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990925 | REC_0010528 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 7 | 74 | female | 1 | 21 | 6.6 | 10 | pembrolizumab 200 mg q3w | 8.3 | true | MSS | 2026-03-15T05:35:59.484332+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685753 | REC_0010529 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 14 | 81 | female | 2 | 15 | 6 | 4 | osimertinib 80 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:35:59.484569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730789 | REC_0010530 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.9 | 74 | female | 2 | 18 | 6 | 5 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:59.484853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850068 | REC_0010531 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.7 | 87 | female | 2 | 16 | 6.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.4 | false | MSS | 2026-03-15T05:35:59.485146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640849 | REC_0010532 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 1.5 | 75 | male | 1 | 10 | 5.7 | 5 | osimertinib 80 mg daily | 4.3 | true | MSS | 2026-03-15T05:35:59.485427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686562 | REC_0010533 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 15.5 | 53 | female | 0 | 7 | 5 | 6 | entrectinib 600 mg daily | 13 | false | MSS | 2026-03-15T05:35:59.485663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121744 | REC_0010534 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 12.5 | 61 | female | 1 | 14 | 7.8 | 1 | alectinib 600 mg BID | 18.5 | false | MSS | 2026-03-15T05:35:59.485897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981325 | REC_0010535 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15.2 | 67 | female | 0 | 17 | 4.7 | 4 | osimertinib 80 mg daily | 16 | true | MSI-H | 2026-03-15T05:35:59.486180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977087 | REC_0010536 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.2 | 67 | female | 1 | 48 | 5.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.7 | true | MSS | 2026-03-15T05:35:59.486406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877179 | REC_0010537 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 7 | 78 | female | 1 | 26 | 6.5 | 6 | alectinib 600 mg BID | 12.7 | false | MSS | 2026-03-15T05:35:59.486679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310349 | REC_0010538 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 5.3 | 69 | female | 1 | 53 | 6.4 | 1 | pembrolizumab 200 mg q3w | 17.5 | false | MSS | 2026-03-15T05:35:59.486909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501471 | REC_0010539 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.5 | 63 | male | 0 | 37 | 6.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.6 | false | MSS | 2026-03-15T05:35:59.487140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783352 | REC_0010540 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.8 | 62 | male | 0 | 12 | 6.3 | 5 | entrectinib 600 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:35:59.487373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217287 | REC_0010541 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.2 | 75 | male | 1 | 47 | 4.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 15 | false | MSS | 2026-03-15T05:35:59.487604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273691 | REC_0010542 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5 | 72 | female | 1 | 45 | 4.9 | 5 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:59.487832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639291 | REC_0010543 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 10.3 | 82 | male | 3 | 26 | 6 | 2 | alectinib 600 mg BID | 19.1 | false | MSI-H | 2026-03-15T05:35:59.488067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931411 | REC_0010544 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 14.3 | 72 | female | 1 | 19 | 3.9 | 4 | osimertinib 80 mg daily | 7.1 | false | MSI-H | 2026-03-15T05:35:59.488412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698982 | REC_0010545 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 15.4 | 75 | female | 2 | 26 | 5.9 | 2 | osimertinib 80 mg daily | 18.7 | true | MSI-H | 2026-03-15T05:35:59.488659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186797 | REC_0010546 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 18.2 | 83 | female | 0 | 14 | 6.3 | 1 | alectinib 600 mg BID | 24.3 | false | MSI-H | 2026-03-15T05:35:59.488897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590325 | REC_0010547 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 36 | 11.7 | 71 | female | 2 | 18 | 4.3 | 6 | osimertinib 80 mg daily | 6.5 | false | MSS | 2026-03-15T05:35:59.489134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956852 | REC_0010548 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 6.8 | 68 | female | 0 | 20 | 5.5 | 7 | alectinib 600 mg BID | 7.9 | false | MSS | 2026-03-15T05:35:59.489379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353537 | REC_0010549 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 19.1 | 64 | male | 0 | 11 | 8.5 | 0 | entrectinib 600 mg daily | 24.4 | true | MSS | 2026-03-15T05:35:59.489645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701930 | REC_0010550 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.8 | 57 | female | 0 | 27 | 4.3 | 6 | alectinib 600 mg BID | 9.3 | true | MSI-H | 2026-03-15T05:35:59.489914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538811 | REC_0010551 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 9.5 | 69 | female | 0 | 15 | 8.6 | 2 | entrectinib 600 mg daily | 21.6 | false | MSS | 2026-03-15T05:35:59.490158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528621 | REC_0010552 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.7 | 59 | female | 1 | 40 | 5.2 | 8 | pembrolizumab 200 mg q3w | 15.2 | false | MSS | 2026-03-15T05:35:59.490395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825156 | REC_0010553 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 10.8 | 70 | female | 1 | 0 | 5.3 | 2 | sotorasib 960 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:59.490634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182954 | REC_0010554 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 16.4 | 67 | female | 0 | 16 | 6.3 | 5 | entrectinib 600 mg daily | 13 | false | MSI-H | 2026-03-15T05:35:59.490865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334371 | REC_0010555 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 12.6 | 83 | male | 2 | 9 | 3.7 | 2 | alectinib 600 mg BID | 31.5 | false | MSS | 2026-03-15T05:35:59.491101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819900 | REC_0010556 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 5.8 | 73 | female | 1 | 35 | 5.8 | 6 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:35:59.491328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615458 | REC_0010557 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 13 | 78 | female | 0 | 21 | 5.4 | 6 | sotorasib 960 mg daily | 16.2 | true | MSI-H | 2026-03-15T05:35:59.491662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896589 | REC_0010558 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 37 | 15.3 | 63 | male | 1 | 21 | 5.4 | 2 | entrectinib 600 mg daily | 23.1 | false | MSI-H | 2026-03-15T05:35:59.491903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347507 | REC_0010559 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 13.3 | 51 | male | 0 | 19 | 8.2 | 5 | sotorasib 960 mg daily | 7 | false | MSS | 2026-03-15T05:35:59.492185+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270355 | REC_0010560 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 7 | 72 | female | 1 | 7 | 5.2 | 1 | osimertinib 80 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:59.492421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517619 | REC_0010561 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 15.5 | 71 | female | 3 | 17 | 4.6 | 2 | pembrolizumab 200 mg q3w | 18.7 | true | MSI-H | 2026-03-15T05:35:59.492654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157850 | REC_0010562 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 6.6 | 66 | female | 1 | 70 | 6.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.3 | true | MSS | 2026-03-15T05:35:59.492882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649308 | REC_0010563 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 35 | 12 | 75 | female | 2 | 12 | 4.6 | 5 | entrectinib 600 mg daily | 6.8 | true | MSI-H | 2026-03-15T05:35:59.493121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639639 | REC_0010564 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 5.9 | 65 | female | 0 | 45 | 4.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 31.3 | false | MSS | 2026-03-15T05:35:59.493350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339457 | REC_0010565 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 14.2 | 56 | female | 1 | 14 | 6.4 | 6 | sotorasib 960 mg daily | 7.9 | false | MSI-H | 2026-03-15T05:35:59.493587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732766 | REC_0010566 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 7.8 | 63 | female | 0 | 19 | 4.7 | 1 | pembrolizumab 200 mg q3w | 11 | true | MSS | 2026-03-15T05:35:59.493818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547391 | REC_0010567 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 34 | 9 | 72 | female | 2 | 16 | 5.4 | 1 | sotorasib 960 mg daily | 21.4 | true | MSS | 2026-03-15T05:35:59.494045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567407 | REC_0010568 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 6.4 | 66 | male | 1 | 11 | 3.8 | 2 | entrectinib 600 mg daily | 4.5 | true | MSS | 2026-03-15T05:35:59.494275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724521 | REC_0010569 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 16.1 | 52 | female | 0 | 10 | 2.6 | 5 | osimertinib 80 mg daily | 8.2 | false | MSI-H | 2026-03-15T05:35:59.494508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653981 | REC_0010570 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 15.6 | 68 | female | 1 | 24 | 5.6 | 7 | entrectinib 600 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:59.494802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167486 | REC_0010571 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.4 | 61 | male | 1 | 14 | 5 | 4 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.495042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632629 | REC_0010572 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 2.9 | 71 | female | 1 | 25 | 5.7 | 4 | alectinib 600 mg BID | 5.7 | false | MSS | 2026-03-15T05:35:59.495273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615165 | REC_0010573 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 15.5 | 76 | female | 1 | 14 | 4.1 | 6 | alectinib 600 mg BID | 9 | true | MSS | 2026-03-15T05:35:59.495503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350743 | REC_0010574 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 14 | 10.5 | 67 | female | 0 | 13 | 5.7 | 1 | osimertinib 80 mg daily | 19 | false | MSI-H | 2026-03-15T05:35:59.495734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293736 | REC_0010575 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 13.7 | 77 | male | 1 | 18 | 6.1 | 1 | alectinib 600 mg BID | 4.2 | false | MSS | 2026-03-15T05:35:59.495970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969997 | REC_0010576 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 10.2 | 63 | female | 1 | 8 | 7.3 | 1 | osimertinib 80 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:35:59.496255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673381 | REC_0010577 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.8 | 59 | male | 0 | 13 | 5.2 | 4 | sotorasib 960 mg daily | 15.6 | true | MSS | 2026-03-15T05:35:59.496508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277250 | REC_0010578 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 8.3 | 53 | female | 0 | 65 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:59.496757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948621 | REC_0010579 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.2 | 73 | female | 2 | 20 | 6.3 | 5 | entrectinib 600 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:59.496990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927919 | REC_0010580 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 8 | 71 | female | 1 | 10 | 6.7 | 8 | osimertinib 80 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:59.497218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690515 | REC_0010581 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.8 | 64 | male | 1 | 19 | 6.2 | 6 | osimertinib 80 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:59.497454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648574 | REC_0010582 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 9.2 | 73 | female | 2 | 13 | 5.4 | 7 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:59.497682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339972 | REC_0010583 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.5 | 69 | female | 1 | 21 | 2.5 | 1 | osimertinib 80 mg daily | 19.9 | false | MSS | 2026-03-15T05:35:59.498047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626682 | REC_0010584 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.7 | 66 | female | 1 | 56 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.4 | true | MSS | 2026-03-15T05:35:59.498281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801266 | REC_0010585 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 3.5 | 82 | female | 2 | 93 | 8.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.7 | true | MSS | 2026-03-15T05:35:59.498511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265785 | REC_0010586 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 33 | 9.4 | 73 | male | 2 | 7 | 4.1 | 0 | alectinib 600 mg BID | 56.4 | true | MSS | 2026-03-15T05:35:59.498762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750156 | REC_0010587 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 17 | 88 | female | 2 | 16 | 4.7 | 4 | alectinib 600 mg BID | 6.7 | false | MSI-H | 2026-03-15T05:35:59.499003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524048 | REC_0010588 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 20.4 | 75 | female | 0 | 11 | 4.7 | 5 | entrectinib 600 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:59.499239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183940 | REC_0010589 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 3.6 | 65 | male | 0 | 24 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 27.1 | true | MSS | 2026-03-15T05:35:59.499473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612851 | REC_0010590 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 14.9 | 74 | female | 2 | 5 | 8.5 | 5 | osimertinib 80 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:35:59.499713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687998 | REC_0010591 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 12.5 | 62 | male | 1 | 15 | 6.1 | 2 | alectinib 600 mg BID | 21.8 | false | MSS | 2026-03-15T05:35:59.499962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583179 | REC_0010592 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 10.6 | 75 | female | 2 | 8 | 3.8 | 8 | entrectinib 600 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:59.500268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307394 | REC_0010593 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 14 | 5.6 | 79 | female | 2 | 58 | 4.7 | 6 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:59.500575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767727 | REC_0010594 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 17.6 | 60 | male | 0 | 14 | 5.1 | 0 | sotorasib 960 mg daily | 49.5 | false | MSS | 2026-03-15T05:35:59.500834+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846232 | REC_0010595 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.2 | 54 | female | 0 | 11 | 5.3 | 8 | osimertinib 80 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:59.501091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235033 | REC_0010596 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 15.6 | 68 | female | 1 | 13 | 7 | 9 | osimertinib 80 mg daily | 13.4 | false | MSI-H | 2026-03-15T05:35:59.501898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327756 | REC_0010597 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 11.3 | 66 | female | 1 | 2 | 5.2 | 4 | sotorasib 960 mg daily | 15.7 | false | MSI-H | 2026-03-15T05:35:59.502171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771180 | REC_0010598 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 17.3 | 73 | female | 2 | 12 | 6.3 | 1 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:59.502415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160250 | REC_0010599 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.3 | 66 | female | 1 | 14 | 5.7 | 7 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:35:59.502648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899043 | REC_0010600 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 5.3 | 61 | female | 0 | 37 | 3.7 | 7 | pembrolizumab 200 mg q3w | 7.4 | false | MSS | 2026-03-15T05:35:59.502888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.